Home › Heart Valve Diseases › Massachusetts › Boston
Heart Valve Diseases clinical trials in Boston, MA
4 studies for Heart Valve Diseases are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
EFS of the DUO System for Tricuspid Regurgitation
Recruiting
- Beth Israel Deaconess Medical Center, Boston
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
Recruiting
- Massachusetts General Hospital, Boston
- Brigham and Women's Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR
Recruiting
- St Elizabeth's Medical Center, Boston
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess, Boston
Allogeneic Valve Transplantation
Recruiting
- Boston Children's Hospital, Boston
About Heart Valve Diseases
Heart valve disease happens when one or more of your heart valves do not open or close correctly. This can affect your blood flow and strain your heart.
More about Heart Valve Diseases on MedlinePlus
Heart Valve Diseases trials in other cities
- New York City, NY11 studies
- Cleveland, OH10 studies
- Phoenix, AZ5 studies
- Cincinnati, OH5 studies
- Chicago, IL5 studies
- Minneapolis, MN5 studies
- Atlanta, GA4 studies
- Pittsburgh, PA4 studies
- Houston, TX4 studies
- Philadelphia, PA4 studies
- Thousand Oaks, CA3 studies
- Ann Arbor, MI3 studies
Other studies in Boston
- Breast Cancer112 studies
- Non-Small Cell Lung Cancer90 studies
- Cancer (all types)85 studies
- Metastatic Cancer63 studies
- Colorectal Cancer63 studies
- Lung Cancer62 studies
- Ovarian Cancer61 studies
- Prostate Cancer59 studies
- Depression52 studies
- Endometrial Cancer50 studies
- Heart Failure44 studies
- Acute Myeloid Leukemia44 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.